NZ503551A - PDE4 inhibitors for the treatment of inflammatory skin diseases - Google Patents

PDE4 inhibitors for the treatment of inflammatory skin diseases

Info

Publication number
NZ503551A
NZ503551A NZ503551A NZ50355198A NZ503551A NZ 503551 A NZ503551 A NZ 503551A NZ 503551 A NZ503551 A NZ 503551A NZ 50355198 A NZ50355198 A NZ 50355198A NZ 503551 A NZ503551 A NZ 503551A
Authority
NZ
New Zealand
Prior art keywords
xanthine
use according
compound
cyclopropylmethyl
butyl
Prior art date
Application number
NZ503551A
Other languages
English (en)
Inventor
Don E Griswold
Siegfried Benjamin Christensen
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NZ503551A publication Critical patent/NZ503551A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NZ503551A 1997-10-17 1998-10-16 PDE4 inhibitors for the treatment of inflammatory skin diseases NZ503551A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6374697P 1997-10-17 1997-10-17
PCT/US1998/021886 WO1999020280A1 (en) 1997-10-17 1998-10-16 Novel use of compounds for anti-pruritic activity

Publications (1)

Publication Number Publication Date
NZ503551A true NZ503551A (en) 2002-05-31

Family

ID=22051225

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ503551A NZ503551A (en) 1997-10-17 1998-10-16 PDE4 inhibitors for the treatment of inflammatory skin diseases

Country Status (18)

Country Link
EP (1) EP1030666A4 (xx)
JP (1) JP2001520196A (xx)
KR (1) KR20010031149A (xx)
CN (1) CN1306426A (xx)
AR (1) AR015966A1 (xx)
AU (1) AU740875B2 (xx)
BR (1) BR9814080A (xx)
CA (1) CA2306985A1 (xx)
CO (1) CO4810374A1 (xx)
CZ (1) CZ20001376A3 (xx)
HU (1) HUP0003792A3 (xx)
IL (1) IL135581A0 (xx)
NO (1) NO20001847D0 (xx)
NZ (1) NZ503551A (xx)
PL (1) PL341062A1 (xx)
TR (1) TR200001040T2 (xx)
WO (1) WO1999020280A1 (xx)
ZA (1) ZA989450B (xx)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7250518B2 (en) 2001-01-31 2007-07-31 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
CA2436535A1 (en) 2001-01-31 2002-08-08 Prizer Products Inc. Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes
EE200300362A (et) 2001-01-31 2003-12-15 Pfizer Products Inc. PDE4 isosüümide inhibiitoritena kasutatavad tiasolüül-, oksasolüül-, pürrolüül- ja imidasolüülhappeamiidi derivaadid
HUP0302891A2 (hu) 2001-01-31 2003-12-29 Pfizer Products Inc. PDE4 izoenzimek inhibitoraiként alkalmazható éterszármazékok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
US20030175314A1 (en) * 2001-11-19 2003-09-18 Didriksen Erik Johannes Pharmaceutical composition for dermal application
EP1647274A4 (en) * 2003-07-17 2008-12-10 Ono Pharmaceutical Co REMEDY AGAINST PRURIT COMPRISING A PIPERIDINE DERIVATIVE AS AN ACTIVE INGREDIENT
JP2005187458A (ja) * 2003-12-04 2005-07-14 Santen Pharmaceut Co Ltd シロミラストまたはその塩を有効成分とする掻痒治療剤
WO2005053672A1 (ja) * 2003-12-04 2005-06-16 Santen Pharmaceutical Co., Ltd. シロミラストまたはその塩を有効成分とする掻痒治療剤
WO2005077950A2 (en) 2004-02-14 2005-08-25 Smithkline Beecham Corporation Medicaments with hm74a receptor activity
JP2008137892A (ja) * 2005-03-04 2008-06-19 Eisai Co Ltd 止痒剤
BRPI0614270A2 (pt) 2005-08-10 2011-03-22 Smithkline Beecham Corp derivados xantina como seletivos agonistas de ha74a
TWI404709B (zh) * 2006-02-21 2013-08-11 Eisai R&D Man Co Ltd 4- (3-benzamidophenyl) -6,7-dimethoxy-2-methylamine quinazoline derivatives
EP1992622B1 (en) * 2006-02-21 2011-07-27 Eisai R&D Management Co., Ltd. 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2- methylaminoquinazoline derivative
EP2123641A4 (en) 2007-02-16 2011-06-22 Eisai R&D Man Co Ltd CRYSTAL, AMORPHOUS FORM AND METHYL N-Ý3- (6,7-DIMETHOXY-2-METHYLAMINOQUINAZOLINE-4-YL) PHENYLENE TEREPHTALIC ACID SALT
CN102336717B (zh) 2007-08-17 2013-09-18 卫材R&D管理有限公司 喹唑啉衍生物
US8513269B2 (en) 2007-08-17 2013-08-20 Eisai R&D Management Co., Ltd. Preparation for external use
US20140121240A1 (en) 2011-06-28 2014-05-01 Maruho Co., Ltd. Novel pharmaceutical composition
EA034139B1 (ru) 2015-01-30 2020-01-09 Шаньтонь Фарма Ко., Лтд. Профилактика или лечение мочекислых или подагрических заболеваний

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0563168B1 (en) * 1990-12-21 2000-07-05 Beecham Group Plc Xanthine derivatives
ATE224386T1 (de) * 1996-03-26 2002-10-15 Altana Pharma Ag Neue in 6-position substituierte phenanthridine
ES2187775T3 (es) * 1996-05-15 2003-06-16 Altana Pharma Ag Imidazopiridinas.
DE69817548T2 (de) * 1997-03-07 2004-06-17 Altana Pharma Ag Tetrazole derivate
PL336464A1 (en) * 1997-03-18 2000-06-19 Basf Ag Method of and compositions for modulating reactivity in respect to corticosteroids i
WO1998055481A1 (en) * 1997-06-03 1998-12-10 Byk Gulden Lomberg Chemische Fabrik Gmbh Benzonaphthyridine

Also Published As

Publication number Publication date
IL135581A0 (en) 2001-05-20
ZA989450B (en) 1999-04-19
AU740875B2 (en) 2001-11-15
TR200001040T2 (tr) 2001-01-22
CA2306985A1 (en) 1999-04-29
KR20010031149A (ko) 2001-04-16
AU1093899A (en) 1999-05-10
WO1999020280A1 (en) 1999-04-29
CZ20001376A3 (cs) 2002-06-12
CN1306426A (zh) 2001-08-01
HUP0003792A3 (en) 2001-12-28
EP1030666A4 (en) 2002-10-16
BR9814080A (pt) 2000-09-26
HUP0003792A2 (hu) 2001-10-28
CO4810374A1 (es) 1999-06-30
NO20001847L (no) 2000-04-10
NO20001847D0 (no) 2000-04-10
AR015966A1 (es) 2001-05-30
EP1030666A1 (en) 2000-08-30
PL341062A1 (en) 2001-03-26
JP2001520196A (ja) 2001-10-30

Similar Documents

Publication Publication Date Title
AU740875B2 (en) Novel use of compounds for anti-pruritic activity
Golightly et al. Pharmaceutical excipients: adverse effects associated with inactive ingredients in drug products (Part I)
JPWO2006041121A1 (ja) 慢性皮膚疾患の治療および／または予防剤
WO2008025543A1 (en) Pharmaceutical compositions for the treatment of fungal infections
WO2008091704A2 (en) Treatment of cushing's syndrome and autism
US6498173B1 (en) Synergistic combination comprising roflumilast and a pde-3 inhibitor
JPS62185014A (ja) 複合調剤薬
CA2136977A1 (en) _-8-tetrahydro-cannabinol as antiemetic
JPH02160720A (ja) 医薬組成物
EP0402422A1 (en) Certain paf antagonist antihistamine combinations and methods
JP3276762B2 (ja) イソキノリン誘導体を含有する医薬組成物
MXPA00003775A (en) Novel use of compounds for anti-pruritic activity
AU763275B2 (en) Viral treatment
ES2378374T3 (es) Inhibidores de la PDE 4 para el tratamiento de la cistitis intersticial
JPH03215435A (ja) アルドース還元酵素阻害剤を主成分とする潰瘍治療剤
AU592851B2 (en) Transdermal formulations
US5981538A (en) Methods of treating psoriasis employing substituted azaspiranes
JPS6245525A (ja) 脂質低下剤
EP0338010B1 (en) Pharmaceutical compositions for treatment of hyperproliferate skin disease
GB1588095A (en) Composition for the treatment of scabies
US20060079513A1 (en) Methods and compositions including methscopolamine nitrate
AU1563902A (en) Novel use of compounds for anti-pruritic activity
JP2004026810A (ja) 鼻炎用組成物
EP2037934A2 (en) An anti-viral composition for the topical treatment of herpes labialis (cold sores) and method for use thereof
JPH0653678B2 (ja) アレルギ−性疾患治療剤

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)